U.S. markets close in 4 hours 51 minutes

Arch Therapeutics, Inc. (ARTH)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.1025-0.0003 (-0.29%)
As of 10:42AM EDT. Market open.

Arch Therapeutics, Inc.

235 Walnut Street
Suite 6
Framingham, MA 01702
United States
617 431 2313

Full Time Employees7

Key Executives

NameTitlePayExercisedYear Born
Dr. Terrence W. NorchiCo-Founder, Chairman, Pres, CEO & Sec.519.2kN/A1965
Mr. Richard E. DavisAdvisor387.26kN/A1958
Dr. Rutledge Ellis-Behnke Ph.D.Co-Founder & Scientific AdvisorN/AN/AN/A
Mr. Michael S. AbramsChief Financial OfficerN/AN/A1970
Dr. Steven A. Kates Ph.D.VP of TechnologyN/AN/AN/A
Dr. Elaine WhitmoreRegulatory Consultant & AdvisorN/AN/AN/A
Mr. Daniel C. Wadsworth Jr.Advisor & Consultant of Wound Care CommercializationN/AN/A1954
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Arch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. The company develops and markets products based on its AC5 self-assembling technology platform to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care or from disease. Its flagship products include AC5 advanced wound system and AC5 topical hemostat, which are intended for skin applications, such as management of complicated chronic wounds or acute surgical wounds. The company was founded in 2006 and is based in Framingham, Massachusetts.

Corporate Governance

Arch Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.